15367-16-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-Hydrazino-3-nitropyridine is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new and effective compounds.
Used in Energetic Materials Production:
2-Hydrazino-3-nitropyridine is utilized as a precursor in the production of energetic materials due to its high-energy content, which is valuable in creating propellants and other explosive substances.
Used in Propellant Formulation:
In the field of propellant formulation, 2-Hydrazino-3-nitropyridine is used as a component to enhance the energy release and performance of propellants, given its explosive properties and reactivity.
Safety Considerations:
Due to the explosive nature of 2-Hydrazino-3-nitropyridine, it is used with strict adherence to safety protocols to prevent accidents and ensure the safe handling and storage of this high-energy material.

InChI:InChI=1/C5H6N4O2/c6-8-5-4(9(10)11)2-1-3-7-5/h1-3H,6H2,(H,7,8)

Upstream product

• 4214-75-9 2-amino-3-nitropyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 1480-87-1 2-fluoro-3-nitropyridine 
• 6332-56-5 2-hydroxy-3-nitropyridine 
• 142-08-5 2-hydroxypyridin 

Downstream Products

• 59696-94-5 (1S)-O⁵-benzoyl-1-(8-nitro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-D-1,4-anhydro-ribitol 
• 73012-62-1 (1R)-O⁵-benzoyl-1-(8-nitro-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-D-1,4-anhydro-arabinitol 
• 132454-30-9 N-(3-Nitro-2-pyridyl) N'-(4'-thia-cyclohexylidene)hydrazine 
• 21126-92-1 N-[1-(5-Nitro-furan-2-yl)-meth-(Z)-ylidene]-N'-(3-nitro-pyridin-2-yl)-hydrazine 
• 101458-28-0 3,3'-dinitro-2,2'-hydrazobipyridine 
• 110606-59-2 ethyl 2-(3-nitro-2-pyridylhydrazono)propionate 
• 110606-60-5 ethyl 2-(3-nitro-2-pyridylhydrazono)phenylacetate 
• 31040-09-2 8-nitro-1,2,4-triazolo[4,3-a]pyridine 
• 76211-91-1 3-nitro-2-(pyrazol-1-yl)-pyridine 
• 88713-42-2 (benzoyloxy-2 ethoxymethyl)-2 nitro-8-s-triazolo<1,5-a>pyridine 
• 78796-82-4 2-(3',4'-di-O-benzoyl-2',6'-dideoxy-L-arabino-hex-1'-enopyranosyl)-8-nitro<1,2,4>triazolo<1,5-a>pyridine 
• 78796-81-3 2-(2',3',4'-tri-O-benzoyl-6'-deoxy-α-L-manno-hexopyranosyl)-8-nitro<1,2,4>triazolo<1,5-a>pyridine 
• 126274-28-0 3-nitro-pirid-2-il-idrazone dell'acetacetilpirrolidina 
• 132454-31-0 N-(3-Nitro-2-pyridyl) N'-cyclopentylidene hydrazine 

Relevant academic research and scientific papers

Synthesis of Hydrazinylpyridines via Nucleophilic Aromatic Substitution and Further Transformation to Bicyclo[22.2]octenes Fused with Two N -Aminosuccinimide Moieties

Efficient and reliable synthesis of substituted hydrazinylpyridines in thick-wall ACE tubes via nucleophilic substitution of a chlorine substituent in different chloropyridines is presented. Hydrazine hydrate and alkylhydrazines were used as nucleophiles and simple alcohols and diethyl ether were the only organic solvents necessary, making the process environmentally and user friendly, potentially reaching 100% atomic efficiency. In the next step, transformations of succinic anhydride moieties fused to the bicyclo[2.2.2]octene framework into succinimide moieties via nucleophilic substitution of oxygens were conducted. As nucleophiles two of the synthesized hydrazinylpyridines (2-hydrazinyl-3-nitropyridine and 2-hydrazinyl-5-nitropyridine) and also hydrazine hydrate, phenylhydrazine, and 4-nitrophenylhydrazine were used. Reactions were again carried out in ACE tubes and only simple alcohols, diethyl ether, and acetone were needed as solvents. One of the prepared bicyclo[2.2.2]octene adducts displayed water solubility thus being a promising candidate for future studies as a novel bidentate ligand for various metal cations in aqueous solutions or acting as an unprecedented halogen bond acceptor.

Pyridine hydrazone derivative as well as preparation method and application thereof (by machine translation)

The invention relates to a pyrazine hydrazone derivative represented I, a pharmaceutically acceptable salt thereof, a pharmaceutical composition and application thereof in preparation of an influenza virus neuraminidase inhibitor. Wherein R-substituted pyridyl is selected from the group consisting of 5 - trifluoromethyl -2 - pyridyl, 3 - nitro -2 - pyridyl; Y is selected from the group consisting of: hydroxy, dihydroxyl, 3 - hydroxy -2 - C1 - C2 alkoxy, 3 - hydroxy -4 - C1 - C2 alkoxy, 3 - hydroxy -5 - C1 - C2, 3 -hydroxy -3 - C1 - C2 -6 - C1 - C2 alkoxy 4 -3 4 - hydroxy -2 - C1 - C2-4 - 5 -C1 - C2 dimethyl, Z is 4 - selected from -3: 5 - CH or N. sub. CO. (by machine translation)

Keeping it small, polar, and non-flat: diversely functionalized building blocks containing the privileged 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]- and [1,5-a]pyridine cores

Six sets of functionalized building blocks based on 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine as well as 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine cores have been prepared. These compounds are non-flat, bicyclic heterocycles that are likely to find utility as privileged motifs for lead-like compound design. One set of building blocks, (5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-6-ylmethyl)amines, proved useful as a scaffold for developing compounds that stimulate glucagon-like peptide-1 (GLP-1) secretion and are novel anti-diabetes drug leads.

NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE

Provided are new biphenyl derivatives of formula (Ia). These compounds act as aromatase and sulfatase inhibitors. They are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, provided are processes for the preparation of these compounds and pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.

Synthesis and pharmacological activity of N-hetaryl-3(5)-nitropyridines

Abstract Previously undescribed 2-, 4or 6-substituted hetaryl-3(5)-nitropyridines were synthesized by the interaction of a number of chlorosubstituted 3(5)-nitropyridines with some diazoles or 3-chloropyridazin-6one. In addition, pyrazolyl-3-nitropyridines were prepared by both the above method and cyclization of hydrazinopyridines, which, in turn, were synthesized by the treatment of chlorosubstituted 3-nitropyridines with hydrazine. It has been shown that these compounds have a moderate antibacterial activity against some pathogenic Gram-positive and Gram-negative bacteria (Staphylococcus aureus and Escherichia coli) and a strong protistocidal effect on protozoa species Colpoda steinii surpassing in this respect clinically used reference drugs.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.

Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO4 in water

A simple dehydrazination reaction has been achieved in the presence of a catalytic amount of CuSO4 for the first time. With CuSO4 (2 mol%) as a catalyst and water as a solvent, the dehydrazination products were obtained in good yields (66-95%). Moreover, the drugs nebularine and vidarabine were afforded successfully, and vidarabine could be produced on a 0.923 kg scale, which shows good potential for industrial applications.

Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors

New potent glycogen synthase kinase-3 (GSK-3) inhibitors, 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives, were designed by modeling, synthesized and evaluated in vitro. Compound 17c showed good potency in enzyme and cell-based assays (IC50 = 111 nM, EC50 = 1.78 μM). Moreover, it has demonstrated desirable water solubility, PK profile, and moderate brain penetration.

Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1)

A series of pyridyl amide/sulfonamide inhibitors of 11β-HSD-1 were modified to incorporate a novel 1,2,4-triazolopyridine scaffold. Optimization of substituents at the 3 and 8 position of the TZP core, with a special focus on enhancing metabolic stability, resulted in the identification of compound 38 as a potent and metabolically stable inhibitor of the enzyme.

1-N-AMINOBENZIMIDAZOLE DERIVATIVES

Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I): wherein R1 and R2 each represents a substituted or unsubstituted alkyl group or the like, R3, R5 and R6 each represents an alkyl group, alkoxy group, hydrogen atom or the like, R4 represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them. The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family. Accordingly, they are useful as peptic ulcer therapeutic agents which are safe and surely bring about therapeutic effects.